Completed Projects

Equity in Perinatal Substance Use Testing

This retrospective chart review examined variations in toxicology testing among women who obtain prenatal care in Massachusetts, to better understand when toxicology tests are utilized and for whom.

Inviting Narratives of SUD treatment in the Perinatal period: a focus on Race and Equity (INSPiRE)

The INSPiRE study sought to learn more about experiences with the healthcare system and community programs for pregnant and parenting individuals with substance use disorder. The project included experts with lived experience and subject matter expertise to design, conduct, and analyze data from individual interviews with pregnant and parenting people of color, specifically Black and Latinx birthing people with SUD to identify barriers to care. Studies have shown disparities in medication use for the treatment of opioid use disorder in pregnancy and the postpartum period for Black and Latinx people as compared to white people. The goal of INSPIRE Project was to use Antiracist Praxis and Community-Enhanced Research in Massachusetts to investigate the intersection of race/ethnicity and substance use disorder (SUD) across the perinatal continuum.

Family Engagement Project

The PRISM team is leading the Family Engagement Project 2.0, with the support the Massachusetts Health Policy Commission (HPC), to continue to support hospitals in developing their ability to engage families impacted by substance use disorders, identify potential sources of inequitable care, incorporate the family voice in local improvement efforts and create supportive spaces to elicit the perspective of families with lived experience.

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)

Funded by the National Institute on Drug Abuse (NIDA) Clinical Trials Network, the MOMs study is a randomized control trial (CTN- 0080) evaluating the impact of two different types of buprenorphine treatment for opioid use disorder in pregnant women. The MOMs trial seeks to compare the effectiveness of sublingual buprenorphine to a long-acting injectable formulation, CAM2038. The MOMs study will follow the health of mother and baby through pregnancy up to one-year post-partum. This multisite trial will enroll 300 participants nationally, with 25 participants recruited locally at MGH.